Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
A recent network meta-analysis took into consideration all the available treatments for UC (except ustekinumab) and concluded that tofacitinib is an efficacious treatment for moderate-to-severe active UC and is likely to be a cost-effective use of NHS resources[105]
Recently Viewed Products 0.00 incl
Some peoples bodies do not produce enough stomach acid or intrinsic factor if they have a condition known as autoimmune atrophic gastritis
Each insurance company in the Blue Cross Blue Shield group sets its own rules and coverage options, which can vary depending on the state and the specific plan you have
US$ 21.32
US$ 23.56
US$ 24.89
US$ 22.45
